EUVIMEDEUVIMED entdecken
Open Access

The Impact of Enrollment Strategies on the Performance of Time‐To‐Event Dose‐Escalation Designs for Phase I Drug Combination Oncology Trials

Xiaowen Tian iD, Michael Sweeting iD, Kristine Broglio iD

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Xiaowen Tian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Antineoplastic Combined Chemotherapy Protocols, Research Design, Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dose‐escalation trials make sequential dosing decisions for cohorts of patients based on accumulating toxicity data, often in the form of dose‐limiting toxicities (DLTs). Challenges arise due to the necessity of complete follow‐up for accurate dosing decisions. There are many settings where patients may become available to be enrolled before there is complete DLT information from the patients already in the trial. In radiotherapy trials, for example, the DLT assessment window is far longer than traditional chemotherapies and waiting for complete DLT information can result in impractically long trial durations. This issue can be exacerbated in escalation trials of dose‐combinations, where the space to be explored and the sample sizes are generally larger. The time‐to‐event (TITE) approach, which utilizes partial follow‐up data, has been effective in reducing trial lengths while ensuring accuracy and safety. Whether TITE methods are beneficial depends critically on the relationship between the DLT assessment window length and patient inter‐arrival time, characterized by the assessment‐to‐interarrival (A/I) ratio. However, the impact of the rate of accrual into the trial and the size of each dosing cohort have not been carefully considered because it is widely assumed that accrual rates will be slow and the A/I ratio will be small. We use comprehensive simulation studies based on a dose‐combination case‐study and show that accrual rates corresponding to larger A/I ratios can result in poor accuracy and safety, while a dosing cohort size of one can additionally induce unfavorable operating characteristics. To address this issue, we propose a modification to the TITE design where the trial is paused if there are a certain number of non‐completers. We demonstrate that this simple modified approach is robust across the range of A/I ratios investigated and has non‐inferior operating characteristics to a non‐TITE design while providing meaningful reductions in trial duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicAntineoplastic Combined Chemotherapy ProtocolsResearch DesignNeoplasmsHumansDose-Response Relationship, DrugTime FactorsSample SizeMaximum Tolerated DoseAntineoplastic Agents

Stichwörter der Autor:innen

combination therapycontinual reassessmentdose‐findinglate‐onset

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Xiaowen Tian, Michael Sweeting, Kristine Broglio

Förderung

  • AstraZeneca

Zitieren

APA

Tian, X., Sweeting, M., & Broglio, K. (2026). The Impact of Enrollment Strategies on the Performance of Time‐To‐Event Dose‐Escalation Designs for Phase I Drug Combination Oncology Trials. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70119

Vancouver

Tian X, Sweeting M, Broglio K. The Impact of Enrollment Strategies on the Performance of Time‐To‐Event Dose‐Escalation Designs for Phase I Drug Combination Oncology Trials. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70119

BibTeX
@article{Tian2026,
  author = {Tian, Xiaowen and Sweeting, Michael and Broglio, Kristine},
  title = {The Impact of Enrollment Strategies on the Performance of Time‐To‐Event Dose‐Escalation Designs for Phase I Drug Combination Oncology Trials},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70119}
}
Kostenlos starten →